Press Releases May 14, 2026 05:25 PM

Flywire to Attend Upcoming Investor Conferences

Flywire to Participate in Key Investor Conferences and Webcast CEO Fireside Chats

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
FLYW

Flywire Corporation announced its participation in upcoming investor conferences including the J.P. Morgan Global Technology, Media, and Communications Conference and the William Blair Annual Growth Stock Conference. CEO Mike Massaro will engage in live fireside chats, webcast on the company's investor relations site, highlighting Flywire's global payments enablement solutions across multiple verticals.

Flywire to Attend Upcoming Investor Conferences
FLYW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Flywire will attend and present at major investor conferences in May and June 2026.
  • CEO Mike Massaro will participate in live fireside chats webcasted for 90 days.
  • Flywire leverages proprietary payment technology across education, healthcare, travel, and B2B sectors supporting payments in over 140 currencies globally.

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW)("Flywire" or the “Company"), a global payments enablement and software company, today announced that the Company will be attending the following upcoming investor conferences:

  • On Wednesday, May 20, 2026, the Company will attend the J.P. Morgan 47th Global Technology, Media, and Communications Conference in Boston, MA. Flywire CEO, Mike Massaro will participate in a fireside chat discussion which will begin at 09:20 am EST.

  • On Thursday, June 4, 2026, the Company will attend the William Blair 46th Annual Growth Stock Conference in Chicago, IL.

The fireside chat discussion will be webcast live from Flywire’s investor relations website at https://ir.flywire.com/. A replay of the webcast will be available on the investor relations website for 90 days following the discussions.

About Flywire
Flywire is a global payments enablement and software company. We combine our proprietary global payments network, next-gen payments platform, and vertical-specific software to deliver the most important and complex payments for our clients and their customers.
Flywire leverages its vertical-specific software and payments technology to deeply embed within the existing A/R workflows for its clients across the education, healthcare, and travel vertical markets, as well as in key B2B industries. Flywire also integrates with leading ERP systems, such as NetSuite, so organizations can optimize the payment experience for their customers while eliminating operational challenges.
Flywire supports approximately 5,100 clients with diverse payment methods in more than 140 currencies across more than 240 countries and territories around the world. The company is headquartered in Boston, MA, USA, with global offices. For more information, visit www.flywire.com. Follow Flywire on XLinkedIn , and Facebook

Contacts
Investor Relations:
Masha Kahn
ir@Flywire.com 

Media:
Sarah King
media@flywire.com


Risks

  • Market reception to Flywire's conference presentations could impact investor sentiment and stock volatility.
  • Competitive pressures in the global payments sector may continue to challenge Flywire's growth.
  • Macroeconomic or regulatory changes affecting cross-border payments could impact Flywire’s business across various verticals.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026